Hiroyuki Nishiyama
A5071455815- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Testicular diseases and treatments
- Epigenetics and DNA Methylation
- Urological Disorders and Treatments
- Prostate Cancer Treatment and Research
- Cancer Research and Treatments
- Lung Cancer Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Immune cells in cancer
- Multiple and Secondary Primary Cancers
- Urinary Bladder and Prostate Research
- Sarcoma Diagnosis and Treatment
- Urologic and reproductive health conditions
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Esophageal Cancer Research and Treatment
- Sperm and Testicular Function
- Renal and related cancers
- Urinary Tract Infections Management
- Reproductive Biology and Fertility
- Peptidase Inhibition and Analysis
University of Tsukuba
2016-2025
University of Tsukuba Hospital
2014-2025
Nihon University Itabashi Hospital
2017-2024
Yamagata University
2023-2024
Chiba University
2024
Queen Mary University of London
2024
University of Sheffield
2024
Barts Health NHS Trust
2024
Sheffield Teaching Hospitals NHS Foundation Trust
2024
Surugadai Nihon University Hospital
2007-2023
Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes.
In response to low ambient temperature, mammalian cells as well microorganisms change various physiological functions, but the molecular mechanisms underlying these adaptations are just beginning be understood. We report here isolation of a mouse cold-inducible RNA-binding protein (cirp) cDNA and investigation its role in cold-stress cells. The cirp encoded an 18-kD consisting amino-terminal RNAbinding domain carboxyl-terminal glycine-rich exhibited structural similarity class stress-induced...
350 Background: The PD-1 inhibitor pembro has durable antitumor activity in pts with metastatic urothelial carcinoma. Upregulation of the pathway been observed BCG-resistant NMIBC, suggesting may benefit. Efficacy and safety HR, BCG-unresponsive NMIBC was evaluated single-arm phase 2 KEYNOTE-057 study; updated results for carcinoma situ (CIS) or without papillary tumor (cohort A) are reported. Methods: Pts histologically confirmed CIS disease, who received adequate BCG therapy were...
Objectives Despite just a 4‐year interval from the last version (2015) of Clinical Practice Guidelines for Bladder Cancer, several dramatic paradigm shifts have occurred in latest clinical practice regarding both diagnosis and treatment bladder cancer. Herein, we updated 2019 Cancer under instruction Japanese Urological Association. Methods We previously reported revision working position paper edition described methods detail. Results The major points change are presented explanations given...
Introduction: Nonmuscle-invasive bladder cancer has a relatively high postoperative recurrence rate despite the implementation of conventional treatment methods. Cystoscopy is essential for diagnosing and monitoring cancer, but lesions are overlooked while using white-light imaging. Using cystoscopy, tumors with small diameter; flat tumors, such as carcinoma in situ; extent associated elevated difficult to identify. In addition, accuracy diagnosis cystoscopy varies according skill experience...
Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC)
Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) disease recurrence after bacillus Calmette-Guérin (BCG) treatment and who ineligible for/refuse radical cystectomy. FGFR alterations commonly detected in NMIBC. We evaluated the activity of oral erdafitinib, a selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, versus intravesical chemotherapy NMIBC select FGFR3/2 following BCG treatment.
Objectives Immune checkpoint inhibitors and enfortumab vedotin have opened new avenues for sequential treatment strategies locally advanced/metastatic urothelial carcinoma (la/mUC). In the pre‐enfortumab era, many patients could not receive third‐line owing to rapid disease progression poor general status. This study aimed analyze real‐world practices la/mUC in Japan, with a focus on who do treatment. Methods We analyzed data 1023 diagnosed between January 2020 December 2021 at 54...
Objective Our study assessed the correlation between discrepancies in clinical and pathological T stages overall survival (OS) patients with upper urinary tract urothelial carcinoma (UTUC), including renal pelvis (UCP) ureter (UCU) carcinoma, treated radical surgery. Methods We utilized data from Japanese Hospital‐Based Cancer Registry (HBCR) to identify UTUC cases ( n = 2376), consisting of UCP 1196) UCU 1180), diagnosed cTa‐3N0M0 2012 2013. All were histologically confirmed solely surgery,...
The glutathione peroxidase 1 gene (GPX1) and the manganese superoxide dismutase (MnSOD) encode main antioxidant enzymes that detoxify endogenous reactive oxygen species involved in carcinogenesis. Polymorphisms of GPX1 MnSOD genes, risk transitional cell cancer bladder were tested.Genotypes leucine (Leu) to proline (Pro) polymorphism at codon 198 GPX1, alanine (Ala) Valine (Val) exon 2 isoleucine threonine 56 determined by a polymerase chain reaction-restriction fragment length technique 213...
Abstract Purpose: The purpose of this study was to identify proteins that are potentially involved in the tumor invasion bladder cancer. Experimental Design: We searched for candidate by comparing profiles secreted among poorly invasive human carcinoma cell line RT112 and highly T24. isolated from culture supernatants were identified shotgun proteomics. found CXCL1 is related cancer cells. also evaluated whether amount chemokine urine would be a potential marker predicting existence tumors....
We evaluated the use of narrow-band imaging (NBI) cystoscopy for detection bladder cancer and analyzed its diagnostic efficacy in cases carcinoma situ (CIS) with known urine cytology results.A prospective controlled study NBI was conducted 104 consecutive patients definite or suspected cancer. Transurethral targeted biopsies were performed after white light (WLI) cystoscopy, histologic outcomes compared.A total 313 taken, including 161 from sites identified as potentially abnormal by and/or...
Cold-inducible RNA-binding protein (Cirp) was the first cold-shock identified in mammals. It is structurally quite different from bacterial proteins and induced response to mild, but not severe, hypothermia. To clarify physiological function of Cirp vivo, we produced cirp -knockout mice. They showed neither gross abnormality nor defect fertility, number undifferentiated spermatogonia significantly reduced recovery spermatogenesis delayed after treatment with a cytotoxic agent, busulfan....